Raymond James upgraded enGene (ENGN) to Strong Buy from Outperform with a price target of $27, up from $23.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene’s Detalimogene Shows Promising Results in Bladder Cancer Trial
- Buy Rating for enGene Holdings Amid Anticipated Positive Data from Phase 2 LEGEND Study
- enGene to Discuss New Data from LEGEND Trial for Bladder Cancer Therapy
- enGene Holdings to Present at Key November Investor Conferences
- enGene Holdings Recognized as a Top Workplace in Life Sciences